Mark DB - Search Results

1

Baseline and 6-month costs of primary angioplasty therapy for acute myocardial infarction: results from the primary angioplasty registry.

Mark DB, O'Neill WW, Brodie B, Ivanhoe R, Knopf W, Taylor G, O'Keefe JH, Grines CL, Davidson-Ray L, Knight JD, et al. Mark DB, et al. J Am Coll Cardiol. 1995 Sep;26(3):688-95. doi: 10.1016/0735-1097(95)00246-z. J Am Coll Cardiol. 1995. PMID: 7642860 Free article. Clinical Trial.

2

Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States.

Mark DB, Naylor CD, Hlatky MA, Califf RM, Topol EJ, Granger CB, Knight JD, Nelson CL, Lee KL, Clapp-Channing NE, et al. Mark DB, et al. N Engl J Med. 1994 Oct 27;331(17):1130-5. doi: 10.1056/NEJM199410273311706. N Engl J Med. 1994. PMID: 7935638 Free article.

3

A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications.

Batchelor WB, Peterson ED, Mark DB, Knight JD, Granger CB, Armstrong PW, Califf RM. Batchelor WB, et al. Among authors: mark db. J Am Coll Cardiol. 1999 Jul;34(1):12-9. doi: 10.1016/s0735-1097(99)00174-6. J Am Coll Cardiol. 1999. PMID: 10399985 Free article.

4

Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era.

Bengtson JR, Kaplan AJ, Pieper KS, Wildermann NM, Mark DB, Pryor DB, Phillips HR 3rd, Califf RM. Bengtson JR, et al. Among authors: mark db. J Am Coll Cardiol. 1992 Dec;20(7):1482-9. doi: 10.1016/0735-1097(92)90440-x. J Am Coll Cardiol. 1992. PMID: 1452920 Free article.

5

Late restenosis after emergent coronary angioplasty for acute myocardial infarction: comparison with elective coronary angioplasty.

Simonton CA, Mark DB, Hinohara T, Rendall DS, Phillips HR, Peter RH, Behar VS, Kong Y, O'Callaghan WG, O'Connor C, et al. Simonton CA, et al. Among authors: mark db. J Am Coll Cardiol. 1988 Apr;11(4):698-705. doi: 10.1016/0735-1097(88)90198-2. J Am Coll Cardiol. 1988. PMID: 2965171 Free article.

6

Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.

Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, Jollis JG, Cleman MW, Lee KL, Aversano T, Untereker WJ, Davidson-Ray L, Califf RM. Mark DB, et al. Circulation. 1996 Aug 15;94(4):629-35. doi: 10.1161/01.cir.94.4.629. Circulation. 1996. PMID: 8772681 Clinical Trial.

7

Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction. The Randomized IABP Study Group. Intraaortic Balloon Pump.

Talley JD, Ohman EM, Mark DB, George BS, Leimberger JD, Berdan LG, Davidson-Ray L, Rawert M, Lam LC, Phillips HR, Califf RM. Talley JD, et al. Among authors: mark db. Am J Cardiol. 1997 Mar 1;79(5):590-4. doi: 10.1016/0002-9149(96)00821-1. Am J Cardiol. 1997. PMID: 9068514 Clinical Trial.

8

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].

Mark DB, Cowper PA, Berkowitz SD, Davidson-Ray L, DeLong ER, Turpie AG, Califf RM, Weatherley B, Cohen M. Mark DB, et al. Circulation. 1998 May 5;97(17):1702-7. doi: 10.1161/01.cir.97.17.1702. Circulation. 1998. PMID: 9591764 Clinical Trial.

9

Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.

Tung CY, Granger CB, Sloan MA, Topol EJ, Knight JD, Weaver WD, Mahaffey KW, White H, Clapp-Channing N, Simoons ML, Gore JM, Califf RM, Mark DB. Tung CY, et al. Among authors: mark db. Circulation. 1999 Jan 26;99(3):370-6. doi: 10.1161/01.cir.99.3.370. Circulation. 1999. PMID: 9918523

10

Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.

Mark DB, Harrington RA, Lincoff AM, Califf RM, Nelson CL, Tsiatis AA, Buell H, Mahaffey KW, Davidson-Ray L, Topol EJ. Mark DB, et al. Circulation. 2000 Feb 1;101(4):366-71. doi: 10.1161/01.cir.101.4.366. Circulation. 2000. PMID: 10653826 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

500 results

Search Page

Filters